News
03-13-2026, 12:54 PM
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.
More... (https://www.news-medical.net/news/20260313/Combined-CDK46-and-EGFR-inhibition-improves-pancreatic-cancer-therapy.aspx)
More... (https://www.news-medical.net/news/20260313/Combined-CDK46-and-EGFR-inhibition-improves-pancreatic-cancer-therapy.aspx)